Cohort A includes tumours harboring suspected BAP1 mutations (in terms of histology, including cholangiocarcinoma, uveal melanoma, mesothelioma or clear cell renal cell carcinoma) with tissue available for BAP1 mutational assessment via NGS or Cohort B (histology-agnostic): tumours with known DNA damage response (DDR) mutations confirmed by CLIA-approved NGS [55]. This evidence concerns the gene BAP1 and mesothelioma.